title: Kinetics of drug interaction with the Kv11.1 potassium channel.
abstract: The Kv11.1 potassium channel is the molecular target for the majority of drugs implicated in acquired long QT syndrome, the most common cause of drug-induced sudden cardiac death, and a common reason for drug restriction or withdrawal from the market. While the IC50 for block of Kv11.1 is commonly used to estimate the risk of acquired long QT syndrome, this approach is crude, and it is widely accepted that the kinetics of drug interactions with the channel are a critical component in understanding their mechanism of action and risk profiles. In this study we report the first directly measured kinetics of block and unblock of Kv11.1 by a QT prolonging drug: the antipsychotic clozapine. Our data show that clozapine binding to Kv11.1 is complex. There are at least two kinetically distinct components to both block and unblock, while the kinetics of unblock are dependent on the dose or duration of drug application. Based on these observations, we have proposed a model incorporating kinetically distinct binding to the open and inactivated states of Kv11.1 that can describe the observed kinetic features of clozapine block and correctly predict the overall affinity and apparent nonstate-dependent interaction of clozapine with Kv11.1. Mechanistic insights into drug block of Kv11.1 gained though detailed kinetic analyses such as this have a potential role in development of drugs targeted to specific channel states to reduce unwanted side effects, as well as in the design of better high-throughput preclinical tests for assessing the proarrhythmic effects of QT prolonging drugs.
authors.affiliation: Mark Cowley Lidwill Research Program in Cardiac Electrophysiology, Victor Chang Cardiac Research Institute, Darlinghurst, New South Wales, Australia (A.P.H., J.H., T.J.C., S.A.M., J.I.V.); St. Vincent's Clinical School, University of New South Wales, Darlinghurst, New South Wales, Australia (A.P.H., J.H., T.J.C., S.A.M., J.I.V.); and Barwon Health, Geelong, Victoria, Australia (M.J.P.).
authors.forename: Adam P
authors.initials: AP
authors.lastname: Hill
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Perrin
authors.forename: Juliane
authors.initials: J
authors.lastname: Heide
authors.forename: Terence J
authors.initials: TJ
authors.lastname: Campbell
authors.forename: Stefan A
authors.initials: SA
authors.lastname: Mann
authors.forename: Jamie I
authors.initials: JI
authors.lastname: Vandenberg
mesh_terms: D000818:Animals; D016466:CHO Cells; D002478:Cells, Cultured; D003024:Clozapine / Q000378:metabolism / Q000493:pharmacokinetics*; D006224:Cricetinae; D003412:Cricetulus; D004347:Drug Interactions / Q000502:physiology; D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000378:metabolism; D007700:Kinetics; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D026902:Potassium Channel Blockers / Q000378:metabolism / Q000493:pharmacokinetics*
chemical_list: D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels; D026902:Potassium Channel Blockers; D003024:Clozapine